Cellectis SA (CLLS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $118.86M
Last updated: Nov 17, 2026 at 10:55 AM ET
Cellectis SA (CLLS) Stock Forecast
Analysts expect Cellectis SA (CLLS) to earn -$0.78 per share in the fiscal year ending Dec 31, 2026, on revenue of $49.65M. Of 5 analysts, 2 rate the stock Buy or Strong Buy, 2 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 3 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 3.00, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 40% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 2 | 40.0% |
| Hold | 2 | 40.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 20.0% |
- Consensus
- Hold
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates fall 8.9%.
- Fiscal year ending Dec 31, 2026
- -$0.78
- EPS consensus, revenue $49.65M
- Fiscal year ending Dec 31, 2027
- -$0.71
- EPS consensus, revenue $45.24M
- Fiscal year ending Dec 31, 2028
- -$1.32
- EPS consensus, revenue $79.64M
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.78 | -$1.16 to -$0.50 | 5 | $49.65M | $29.89M to $66.29M | 4 |
| Dec 31, 2027 | -$0.71 | -$1.25 to -$0.41 | 4 | $45.24M | $21.63M to $64.50M | 4 |
| Dec 31, 2028 | -$1.32 | -$2.55 to -$0.36 | 2 | $79.64M | $35.16M to $136.40M | 1 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.18 | -$0.26 to -$0.12 | 7 | $13.69M | $9.80M to $18.23M | 7 |
Estimate Revisions
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 3 | 2 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.89.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.78 | -$0.79 | -$0.82 | -$0.89 | -$0.89 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.71 | -$0.84 | -$0.82 | -$0.89 | -$0.89 | N/A |
Frequently Asked Questions About CLLS
What is the CLLS stock forecast?
Consensus analyst estimates put Cellectis SA's EPS at -$0.78 for the fiscal year ending Dec 31, 2026, on revenue of $49.65M. The consensus rating from 5 analysts is Hold.
How do analysts rate CLLS stock?
Of 5 analysts covering Cellectis SA, 0 rate it Strong Buy, 2 Buy, 2 Hold, 0 Sell and 1 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from CLLS next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.78, with estimates from -$1.16 to -$0.50 from 5 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.71, with estimates from -$1.25 to -$0.41 from 4 analysts.
What revenue do analysts expect from Cellectis SA next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $49.65M, with estimates from $29.89M to $66.29M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $45.24M, with estimates from $21.63M to $64.50M.
How many analysts cover CLLS?
5 analysts rate Cellectis SA stock, and 5 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CLLS pages: Overview, Earnings, Forecast, Financials, Competitors